| |
Long-Acting Treatment & PrEP Key Studies at IAS 2021
|
| |
| |
every 6 months, once-monthly, every 1-2 months. Long-Acting Cabotegravir/RPV Implementation Studies; Many studies on Long-Acting Preferences & Acceptability
IAS: Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020 - (07/20/21)
IAS: Outcomes of Participants Switching from F/TDF to F/TAF for PrEP: Week 48 Results from the DISCOVER Open Label Phase - (07/21/21)
IAS: Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDF - (07/20/21)
PrEP for Women
IAS: Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open¬ label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy - (08/23/21)
IAS: Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Engaged in Transactional Sex - (08/23/21)
IAS:
Good Adherence to Vaginal Ring and
Daily PrEP in Half of Young African Women - (07/22/21)
IAS: Barriers to Expanding PrEP Uptake among cis-gender African American Women in the US South - (07/22/21)
IAS: HPTN083 Understanding participant experiences and preferences in an injectable PrEP trial: A qualitative substudy of barriers, facilitators, and preferences for PrEP use among MSM and TGW - (07/22/21)
IAS: Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 - (07/21/21)
Long-Acting Treatment: Cabotegravir/rilpivirine
IAS: Only 1 More Virologic Failure on CAB + RPV in Weeks 96 to 124 of FLAIR - (07/21/21)
IAS: WEEK 124 OF THE RANDOMIZED, OPEN-LABEL, PHASE 3 FLAIR STUDY EVALUATING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR TREATMENT IN ADULTS WITH HIV-1 INFECTION - (07/21/21)
IAS: CAB + RPV Failure Risk Factor in 10% of Large French Cohort - (07/21/21)
IAS: Prevalence of genotypic baseline risk factors of Cabotegravir + Rilpivirine failure among ARV-naïve patients - (07/21/21)
IAS: CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS - (07/20/21)
IAS: CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA - (07/20/21)
IAS: CAB + RPV LA IMPLEMENTATION OUTCOMES AND ACCEPTABILITY OF MONTHLY CLINIC VISITS IMPROVED DURING COVID-19 PANDEMIC ACROSS US HEALTHCARE CLINICS (CUSTOMIZE: HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY) - (07/20/21)
Every 6 months Lenacaprevir or daily pills. Treatment, PrEP
IAS: Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) - (07/20/21)
IAS: Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) - (07/20/21)
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV - (03/15/21)
Every 6 Months PrEP
IAS: Long-acting Capsid Inhibitor Effective as PrEP Against Vaginal SHIV Transmission in Macaques - (07/22/21)
Once-Monthly Islatravir PrEP
IAS: Safety and Pharmacokinetics of Oral Islatravir Once Monthly for HIV Pre-exposure Prophylaxis (PrEP): Week 24 Analysis of a Phase 2a Trial - (07/22/21)
Long-Acting Preferences & Acceptability
IAS: Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US - Online Survey - (07/22/21)
IAS: US MSM Seem Eager for Injectable PrEP-Side Effects, Cost Biggest Concerns - (07/23/21)
IAS: High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide online sample of United States men who have sex with men, 2019 - (07/22/21)
IAS: Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis - (07/22/21)
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) - (07/09/21)
IAS: ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 - (07/19/21)
IAS: New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - (07/19/21)
IAS: Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021 - (07/12/21)
|
|
| |
| |
|
|
|
